サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536217

神経内分泌腫瘍治療薬の世界市場

Neuroendocrine Tumors Therapeutics

出版日
ページ情報
英文 171 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
神経内分泌腫瘍治療薬の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 171 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経内分泌腫瘍治療薬の世界市場は2030年までに66億米ドルに達する見込み

2023年に35億米ドルと推定される神経内分泌腫瘍治療薬の世界市場は、分析期間2023-2030年にCAGR 9.5%で成長し、2030年には66億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるソマトスタチン類似体は、CAGR 8.5%を記録し、分析期間終了時には38億米ドルに達すると予測されます。標的療法分野の成長率は、分析期間中CAGR 11.5%と推定されます。

米国市場は9億1,740万米ドルと推定、中国はCAGR 8.0％で成長予測

米国の神経内分泌腫瘍治療薬市場は、2023年に9億1,740万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに9億7,060万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは8.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.3％と9.0％と予測されています。欧州では、ドイツがCAGR 3.9%で成長すると予測されています。

主要動向と促進要因

神経内分泌腫瘍（NET）は、全身の神経内分泌細胞から発生する複雑ながん群であり、多面的な治療アプローチが必要とされます。これらの腫瘍はその挙動が大きく異なり、しばしば成長が遅く無症状であるため、早期診断と治療が複雑です。NETsの治療には、一般的に手術、ホルモン療法、化学療法、標的生物学的療法が組み合わされ、それぞれが腫瘍のタイプ、部位、遺伝子プロファイルに合わせて行われます。近年、NETの生物学に対する理解が大きく進展し、新たな標的療法の開発や診断技術の向上が推進されています。

NETの研究が進むにつれて、ペプチド受容体放射性核種療法（PRRT）や新規ソマトスタチン類似体などの新しい治療法が登場し、この稀な疾患の管理改善に希望をもたらしています。これらの治療法の開発は、神経内分泌腫瘍の正確な局在を示すガリウム-68ドタテートPETスキャンなどの画像診断の革新によって補完されています。これらの技術的進歩は、診断の精度を高めるだけでなく、治療効果を効果的にモニタリングすることを可能にし、それによって患者の管理戦略を最適化します。

神経内分泌腫瘍治療薬市場の成長は、NETに対する認識の高まり、診断方法の進歩、腫瘍増殖に関与する特定の分子経路を標的とする革新的治療のイントロダクションなど、いくつかの要因によって牽引されています。さらに、NETsの有病率の上昇と世界人口の高齢化は、効果的な治療に対する需要の拡大に寄与しています。製薬会社は、より有効で毒性の低い治療法の開発に投資を続けており、規制当局は、アンメットメディカルニーズに対応する医薬品の早期承認プロセスを通じて、こうした取り組みを支援しています。

調査対象企業の例（全86件）

  • AbbVie, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • HUTCHMED
  • Ipsen Pharma
  • Isotopen Technologien MA1/4nchen
  • Lantheus Holdings, Inc.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP26823

Global Neuroendocrine Tumors Therapeutics Market to Reach US$6.6 Billion by 2030

The global market for Neuroendocrine Tumors Therapeutics estimated at US$3.5 Billion in the year 2023, is expected to reach US$6.6 Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2023-2030. Somatostatin Analogs, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 11.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$917.4 Million While China is Forecast to Grow at 8.0% CAGR

The Neuroendocrine Tumors Therapeutics market in the U.S. is estimated at US$917.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$970.6 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.3% and 9.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Key Trends and Drivers

Neuroendocrine tumors (NETs) represent a complex group of cancers arising from neuroendocrine cells throughout the body, requiring multifaceted treatment approaches. These tumors vary widely in their behavior, often being slow-growing and asymptomatic, which complicates early diagnosis and treatment. The management of NETs typically involves a combination of surgery, hormonal therapy, chemotherapy, and targeted biological therapies, each tailored to the tumor type, location, and genetic profile. Recent years have seen significant advancements in the understanding of NET biology, driving the development of new targeted therapies and improving diagnostic techniques.

As research into NETs advances, new therapeutic options such as peptide receptor radionuclide therapy (PRRT) and novel somatostatin analogs have emerged, offering hope for improved management of this rare condition. The development of these therapies is complemented by innovations in diagnostic imaging, such as Gallium-68 DOTATATE PET scans, which provide precise localization of neuroendocrine tumors. These technological advancements not only enhance the accuracy of diagnosis but also allow for the effective monitoring of treatment response, thereby optimizing patient management strategies.

The growth in the neuroendocrine tumors therapeutics market is driven by several factors, including increased awareness of NETs, advancements in diagnostic methods, and the introduction of innovative treatments that target specific molecular pathways involved in tumor growth. Additionally, the rising prevalence of NETs and the aging global population contribute to the expanding demand for effective treatments. Pharmaceutical companies continue to invest in the development of more efficacious and less toxic therapeutic options, while regulatory agencies support these initiatives through accelerated approval processes for drugs that address unmet medical needs in the NET patient community.

Select Competitors (Total 86 Featured) -

  • AbbVie, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • HUTCHMED
  • Ipsen Pharma
  • Isotopen Technologien MA1/4nchen
  • Lantheus Holdings, Inc.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Neuroendocrine Tumors Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence and Awareness of Neuroendocrine Tumors
    • Advances in Molecular Diagnostics Enhancing Treatment Selection
    • New Developments in Targeted Radionuclide Therapies
    • Expanding Use of Genomic Profiling in Therapy Choices
    • Impact of Immuno-Oncology on NETs Treatment
    • Growing Importance of Multidisciplinary Care Teams
    • Increasing Number of FDA Approvals for Novel Therapies
    • Innovations in Drug Delivery Systems
    • Clinical Trials Addressing Unmet Needs in NET Treatment
    • Economic Impacts of Long-Term Cancer Treatment
    • Partnerships Between Biotech Firms and Academic Centers
    • Regulatory Support for Accelerated Drug Development
    • Investment Trends in Oncology Research
    • Demand for Personalized Medicine and Companion Diagnostics
    • Impact of Aging Populations on Cancer Prevalence
    • Challenges in Managing Chronic and Late-Stage NETs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neuroendocrine Tumors Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neuroendocrine Tumors Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Somatostatin Analogs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Product Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Product Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Product Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Neuroendocrine Tumors Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION